Press Releases
September 13, 2023
HOOKIPA Announces Executive Leadership Change
September 12, 2023
HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
September 6, 2023
HOOKIPA Pharma to participate in upcoming investor conferences in September
August 10, 2023
HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights
August 3, 2023
HOOKIPA Pharma to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 10, 2023
June 10, 2023
HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
May 31, 2023
HOOKIPA Pharma Announces Pricing of $50.0 Million Public Offering of Common Stock and Non-Voting Convertible Preferred Stock
May 31, 2023
HOOKIPA Pharma Announces Positive Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab in Patients with HPV16+ Head and Neck Cancers
May 11, 2023
HOOKIPA Pharma Reports First Quarter 2023 Financial Results and Recent Business Highlights
May 9, 2023
HOOKIPA Announces First Person Dosed in Phase 1a/b Clinical Trial of HB-400, in Collaboration with Gilead, for Treatment of Hepatitis B
May 4, 2023
HOOKIPA Pharma to Participate in Upcoming Investor Conferences in May
May 4, 2023
HOOKIPA Pharma to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 11, 2023
April 26, 2023
HOOKIPA to Present a Trial in Progress Poster on its Prostate Cancer Phase 1/2 Clinical Trial at ASCO
April 19, 2023
HOOKIPA Pharma to Participate in the Van Lanschot Kempen Life Sciences Conference
April 14, 2023
HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
March 15, 2023
HOOKIPA Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook
March 13, 2023
HOOKIPA Pharma Appoints Terry Coelho to its Board of Directors
March 8, 2023
HOOKIPA Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 15, 2023